Arbutus Biopharma Corp (NASDAQ: ABUS) is 23.60% higher on its value in year-to-date trading and has touched a low of $1.69 and a high of $3.29 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ABUS stock was last observed hovering at around $3.12 in the last trading session, with the day’s loss setting it -0.03%.
Currently trading at $3.09, the stock is 16.63% and 15.54% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.22 million and changing -0.96% at the moment leaves the stock 38.53% off its SMA200. ABUS registered 6.55% gain for a year compared to 6-month gain of 62.63%. The firm has a 50-day simple moving average (SMA 50) of $23.68 and a 200-day simple moving average (SMA200) of -$6.05.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 14.44% loss in the last 1 month and extending the period to 3 months gives it a 24.10%, and is 20.70% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.53% over the week and 5.65% over the month.
Arbutus Biopharma Corp (ABUS) has around 73 employees, a market worth around $554.62M and $18.14M in sales. Profit margin for the company is -401.57%. Distance from 52-week low is 82.84% and -6.08% from its 52-week high. The company has generated returns on investments over the last 12 months (-63.73%).
Arbutus Biopharma Corp quarterly earnings per share for the current quarter are estimated at -$0.11 with sales reaching $2.15M over the same period.The EPS is expected to shrink by -1.36% this year, but quarterly earnings will post -57.20% year-over-year. Quarterly sales are estimated to shrink -67.80% in year-over-year returns.
Arbutus Biopharma Corp (ABUS) Top Institutional Holders
146 institutions hold shares in Arbutus Biopharma Corp (ABUS), with institutional investors hold 57.55% of the company’s shares. The shares outstanding are 169.87M, and float is at 134.00M with Short Float at 3.08%. Institutions hold 44.06% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 9.97 million shares valued at $22.93 million. The investor’s holdings represent 5.95% of the ABUS Shares outstanding. As of Jun 29, 2023, the second largest holder is Two Seas Capital Lp with 8.28 million shares valued at $19.05 million to account for 4.94% of the shares outstanding. The other top investors are Whitefort Capital Management, LP which holds 8.09 million shares representing 4.83% and valued at over $18.62 million, while Vanguard Group Inc holds 3.47% of the shares totaling 5.82 million with a market value of $13.38 million.
Arbutus Biopharma Corp (ABUS) Insider Activity
The most recent transaction is an insider sale by McElhaugh Michael J.,the company’sInterim President & CEO. SEC filings show that McElhaugh Michael J. sold 10,164 shares of the company’s common stock on Feb 02 ’24 at a price of $2.31 per share for a total of $23504.0. Following the sale, the insider now owns 1.5 million shares.
Arbutus Biopharma Corp disclosed in a document filed with the SEC on Feb 02 ’24 that Sofia Michael J. (Chief Scientific Officer) sold a total of 9,982 shares of the company’s common stock. The trade occurred on Feb 02 ’24 and was made at $2.31 per share for $23083.0. Following the transaction, the insider now directly holds 1.49 million shares of the ABUS stock.
Still, SEC filings show that on Feb 02 ’24, HASTINGS DAVID C (Chief Financial Officer) disposed off 9,593 shares at an average price of $2.31 for $22184.0. The insider now directly holds 181,907 shares of Arbutus Biopharma Corp (ABUS).
